On the stock market since 2010, it operates in the world of health and science. It has 27,057 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (2% a year).
If every debt were paid off today, $3.1B would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
There is $23.8B in the vault; even if every debt were paid off, $3.1B would remain.
It pays out $0.12 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
On our five-subject report card, GZPHF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GZPHF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.